Clinical Trial Update: Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating fondaparinux in patients with heparin-induced thrombocytopenia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heparin-induced Thrombocytopenia

Drugs mentioned

• Fondaparinux (fondaparinux)

Snippet

Sponsor: Methodist Healthcare | Conditions: Heparin-Induced Thrombocytopenia | Phase 4 | Status: WITHDRAWN